Sustained virologic response following HCV eradication in two brothers with X-linked agammaglobulinaemia.
X-linked agammaglobulinaemia (XLA) is a humoral immunodeficiency syndrome characterized from childhood by the absence of circulating B lymphocytes, absent or reduced levels of serum immunoglobulin and recurrent bacterial infections. For many affected patients, regular treatment with immunoglobulin is life saving. Hepatitis C viral (HCV) infection acquired through contaminated blood products is widely described in this patient cohort. The natural history of HCV infection in patients with XLA tends to follow a more rapid and aggressive course compared to immunocompetent individuals. Furthermore, standard anti-viral therapy appears to be less efficacious in this patient cohort. Here we report the cases of two brothers with XLA who contracted HCV through contaminated blood products. They were treated with a six month course of Interferon alpha-2b and Ribavirin. We report a sustained virologic response five years after completing treatment.
Houlihan
Diarmaid D
DD
Department of Gastroenterology, University College Hospital Galway, Newcastle Road, Galway, Ireland. diarmaidhoulihan@hotmail.com
Storan
Eoin R
ER
Lee
John M
JM
D000328:Adult; D000361:Agammaglobulinemia / Q000150:complications / Q000209:etiology / Q000235:genetics / Q000821:virology*; D000998:Antiviral Agents / Q000627:therapeutic use*; D015897:Comorbidity; D004340:Drug Contamination; D040181:Genetic Diseases, X-Linked / Q000150:complications / Q000235:genetics / Q000821:virology*; D006526:Hepatitis C / Q000097:blood* / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D011994:Recombinant Proteins; D012008:Recurrence; D012254:Ribavirin / Q000627:therapeutic use; D035781:Siblings
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin
Am J Med. 1988 Jan;84(1):107-11
3122562
QJM. 1999 Aug;92(8):433-41
10627859
Clin Immunol. 2001 Dec;101(3):284-8
11726220
Clin Immunol. 2002 Sep;104(3):231-6
12217332
Gut. 1999 Jun;44(6):874-80
10323892
Pediatrics. 1996 Aug;98(2 Pt 1):211-5
8692620
Lancet. 1992 Sep 19;340(8821):697-8
1355801
Clin Exp Immunol. 1995 Oct;102(1):11-6
7554376
J Immunol. 1985 May;134(5):3070-4
3920309
Lancet. 1987 Mar 7;1(8532):539-41
2434816
Clin Dev Immunol. 2006 Jun-Dec;13(2-4):223-59
17162365
N Engl J Med. 1994 Dec 15;331(24):1607-11
7526215
Hepatology. 1998 Dec;28(6):1687-95
9828236
Blood. 1997 Aug 1;90(3):1309-14
9242566
Clin Exp Immunol. 1989 Oct;78(1):1-6
2530014
Clin Exp Immunol. 1997 Oct;110(1):4-8
9353141